MedTrace Logo

Genetic Assessment of Early to Late Macular Degeneration Study

NCT01464710 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2019-06-21

No results posted yet for this study

Summary

The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with early AMD (soft confluent drusen\>120 microns ) in the study eye, and with either early AMD or advanced AMD in the non-study eye.

Conditions

  • Age-related Macular Degeneration

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Henry Ferreyra

    lead OTHER

Principal Investigators

  • Henry Ferreyra, M.D · University of California, San Diego

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01464710 on ClinicalTrials.gov